BAT Announces Repurchase of 74,186 Shares as Part of Ongoing Buyback Program

Nov.28.2024

BAT Announces Repurchase of 74,186 Shares as Part of Ongoing Buyback Program

BAT has repurchased 74,186 shares from Merrill Lynch International, reducing its share count to 2.21 billion, enhancing shareholder value through potential EPS growth.

British American Tobacco PLC (BAT) has repurchased 74,186 ordinary shares at an average price of 2,999.38 pence per share from Merrill Lynch International. This repurchase forms part of the Company's ongoing buyback program, as announced on 28 November.

The transaction, initially announced on 18 March 2024 and authorized by shareholders at the Company's Annual General Meeting on 24 April 2024, was completed on 27 November 2024.

Key details of the transaction are as follows:

Date of purchase: 27 November 2024

Number of shares repurchased: 74,186

Highest price paid per share: 3,010.00 pence

Lowest price paid per share: 2,978.00 pence

Volume weighted average price paid per share: 2,999.38 pence

After the purchase and cancellation, BAT's total number of ordinary shares in issue (excluding treasury shares) will be 2,210,937,032.

This reduction in shares is part of a strategic decision designed to enhance shareholder value by potentially increasing earnings per share.

Additionally, shareholders may need to assess whether they are required to notify any changes to their interest in the company, in accordance with the FCA's Disclosure Guidance and Transparency Rules.

References:

[1] BAT Stock Exchange announcements

#Europe #United Kingdom #Market #Major companies

Glas, the FDA, and the Future of Flavored ENDS

Glas, the FDA, and the Future of Flavored ENDS

China Tobacco Regulation Shift：Policy Updates and Market Impact

China Tobacco Regulation Shift：Policy Updates and Market Impact

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework

At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.

BlackRock Enters Top Shareholder Ranks as KT&G Holding Reaches 5.01%

BlackRock Enters Top Shareholder Ranks as KT&G Holding Reaches 5.01%

BlackRock increased its stake in KT&G to 5.01% after purchasing 68,646 shares, bringing total holdings to 5,914,169 shares and triggering Korea’s large-shareholding disclosure rules. KT&G shares climbed to an all-time intraday high of 153,900(about US$106.19) won and closed at a record 152,900(about US$105.50) won. KT&G is set to report earnings on Feb. 5, with consensus pointing to year-on-year growth in revenue and operating profit.

Jan.30 by 2FIRSTS.ai

KT&G Integrates “lil Aible” Dedicated Stick Lineup Under the “AIIM” Brand

KT&G said it will integrate the Real, Granular and Vapor Stick product lines for its heated tobacco device “lil Aible” under the “AIIM” brand. The company said the brand integration is intended to organize the existing lineup more intuitively and improve consumer accessibility and convenience.

Mar.18 by 2FIRSTS.ai

Shanghai releases 2025 smoke-free white paper: smoking incidence at designated smoke-free venues falls to 12.6%

Shanghai releases 2025 smoke-free white paper: smoking incidence at designated smoke-free venues falls to 12.6%

Shanghai released its 2025 White Paper on Smoking Control in Public Places at a city tobacco control meeting on March 5. The paper reports a 12.6% smoking incidence in legally designated smoke-free venues, down 0.4 percentage points from 2024, and says 98.2% of residents support a full indoor smoking ban.

New Zealand Vape Company Alt Becomes Government Partner After Suing Over Nicotine Limits

New Zealand Vape Company Alt Becomes Government Partner After Suing Over Nicotine Limits

Health NZ signed a NZD 500,000 contract with New Zealand-owned vape company Alt NZ Limited in December 2025 for its free vape kit programme for smokers, with more than 7,000 kits distributed so far.

Mar.23 by 2FIRSTS.ai

PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries

PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries

At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.

Related Topics

Related Read

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework

BlackRock Enters Top Shareholder Ranks as KT&G Holding Reaches 5.01%

BlackRock Enters Top Shareholder Ranks as KT&G Holding Reaches 5.01%

KT&G Integrates “lil Aible” Dedicated Stick Lineup Under the “AIIM” Brand

Shanghai releases 2025 smoke-free white paper: smoking incidence at designated smoke-free venues falls to 12.6%

Shanghai releases 2025 smoke-free white paper: smoking incidence at designated smoke-free venues falls to 12.6%

New Zealand Vape Company Alt Becomes Government Partner After Suing Over Nicotine Limits

New Zealand Vape Company Alt Becomes Government Partner After Suing Over Nicotine Limits

PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries

PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries